Peptide Schedule
CGRP (Calcitonin Gene-Related Peptide)37 residuesACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAFEach bubble = one amino acid. Size = residue mass. Color = chemical class.CGRP (Calcitonin Gene-Related Peptide)
Benefits
About CGRP (Calcitonin Gene-Related Peptide)
Calcitonin Gene-Related Peptide (CGRP) is a 37-amino-acid neuropeptide first identified in 1982 by Amara and colleagues through analysis of alternative RNA processing of the calcitonin gene (CALCA). It exists as two isoforms: alpha-CGRP, produced by alternative splicing of calcitonin mRNA predominantly in sensory neurons, and beta-CGRP, encoded by a separate gene (CALCB) with 94% homology, expressed primarily in enteric neurons. Alpha-CGRP is one of the most abundant neuropeptides in the human body and the most widely studied isoform. CGRP belongs to the calcitonin peptide family alongside calcitonin, amylin, adrenomedullin, and intermedin, all of which signal through Class B G protein-coupled receptors composed of calcitonin receptor-like receptor (CLR) paired with receptor activity-modifying proteins (RAMPs). CGRP signals specifically through the CLR/RAMP1 complex. As the most potent endogenous vasodilator identified, CGRP is approximately 1,000-fold more potent than acetylcholine in relaxing vascular smooth muscle. It is densely expressed in sensory C-fibers and thinly myelinated A-delta fibers of the trigeminal ganglion, dorsal root ganglia, and perivascular sensory nerve terminals throughout the cardiovascular system. CGRP plays dual roles in the nervous system: as a sensory neurotransmitter in nociceptive signaling and as a potent vasoactive peptide in vascular regulation. The discovery that CGRP levels rise in jugular venous blood during migraine attacks (Goadsby et al., 1990) and that intravenous CGRP infusion provokes migraine-like headache in migraineurs (Lassen et al., 2002) established it as the central molecular target in migraine pathophysiology. This led to one of the most successful drug development programs in modern neurology: four monoclonal antibodies (erenumab/Aimovig targeting CLR/RAMP1; fremanezumab/Ajovy, galcanezumab/Emgality, and eptinezumab/Vyepti targeting the CGRP ligand) and three small-molecule CGRP receptor antagonists (gepants: ubrogepant/Ubrelvy, rimegepant/Nurtec, atogepant/Qulipta) have received FDA approval for migraine prevention or acute treatment between 2018 and 2022. Beyond migraine, CGRP has cardioprotective properties — it limits infarct size in ischemia-reperfusion injury models, promotes angiogenesis, and protects against heart failure progression. CGRP promotes wound healing by stimulating keratinocyte proliferation, enhancing dermal microvascular perfusion, and modulating local immune responses. In the gastrointestinal tract, CGRP contributes to mucosal protection and regulates gastric acid secretion. CGRP also plays roles in bone metabolism, lymphocyte regulation, and neurogenic inflammation. Despite extensive research, exogenous CGRP administration has not advanced to approved therapy due to its extremely short plasma half-life (~6.9 minutes), potent systemic vasodilation causing flushing and hypotension, and the advent of far more clinically practical anti-CGRP biologics. The peptide itself remains a critical research tool for understanding trigeminal neurovascular physiology, pain signaling, and cardiovascular regulation.
Who Should Consider CGRP (Calcitonin Gene-Related Peptide)
- Migraine and headache neuroscience researchers
- Cardiovascular researchers studying endogenous vasodilatory mechanisms
- Wound healing and tissue repair investigators
- Pain neuroscience researchers studying trigeminal neurovascular physiology
- Pharmacologists studying GPCR signaling through CLR/RAMP complexes
- Vascular biologists investigating angiogenesis and ischemia-reperfusion injury
How CGRP (Calcitonin Gene-Related Peptide) Works
CGRP signals through a heterodimeric receptor complex consisting of calcitonin receptor-like receptor (CLR), a Class B G protein-coupled receptor, and receptor activity-modifying protein 1 (RAMP1), which confers ligand specificity. An additional intracellular protein, receptor component protein (RCP), is required for efficient G protein coupling. Upon CGRP binding, the CLR/RAMP1 complex primarily activates Gs-coupled signaling, stimulating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP). In vascular smooth muscle cells, elevated cAMP activates protein kinase A (PKA), which phosphorylates potassium-sensitive ATP channels (KATP channels) and myosin light chain phosphatase, leading to smooth muscle relaxation and vasodilation. CGRP-mediated vasodilation also involves endothelium-dependent mechanisms through nitric oxide (NO) release via endothelial nitric oxide synthase (eNOS) activation in some vascular beds. In addition to Gs, CGRP receptor activation engages Gq signaling in certain cell types, activating phospholipase C and increasing intracellular calcium. The receptor also signals through beta-arrestin pathways, leading to receptor internalization into endosomes where sustained cAMP signaling occurs — a phenomenon that may explain the prolonged vasodilatory effects observed despite rapid peptide degradation. In trigeminal sensory neurons, CGRP is synthesized in the cell body, transported to both central terminals (in the trigeminal nucleus caudalis) and peripheral terminals (in the dura mater and cerebral vasculature), and released upon depolarization in a calcium-dependent manner. Meningeal CGRP release from trigeminal afferents causes dural vasodilation, mast cell degranulation, plasma protein extravasation, and sensitization of second-order trigeminocervical neurons — the core pathophysiology of migraine. CGRP also acts in an autocrine/paracrine manner, sensitizing its own release from neighboring sensory neurons, creating a positive feedback loop that amplifies and sustains the migraine attack. In the cardiovascular system, CGRP-containing perivascular sensory nerves densely innervate coronary, cerebral, and mesenteric arteries. During ischemia, capsaicin-sensitive sensory neurons release CGRP as a protective response, mediating ischemic preconditioning via PKC-epsilon and KATP channel-dependent pathways. CGRP also promotes endothelial cell proliferation and angiogenesis through VEGF upregulation. In wound healing, CGRP released from cutaneous sensory nerve terminals stimulates keratinocyte proliferation via cAMP/PKA signaling, enhances local blood flow, modulates Langerhans cell function, and promotes dermal fibroblast migration. In bone, CGRP stimulates osteoblast differentiation and inhibits osteoclast-mediated resorption, contributing to coupling of sensory innervation with bone remodeling.
What to Expect
Rapid onset of vasodilatory effects following IV infusion. Facial flushing and warmth detectable within 1-2 minutes. Measurable reduction in systemic vascular resistance and blood pressure. Heart rate increases reflexively. Peak plasma CGRP concentrations achieved during infusion.
Sustained vasodilation during infusion period. Blood pressure nadir typically reached during or shortly after the infusion. Skin temperature elevation in extremities. In migraine-susceptible individuals, premonitory migraine symptoms may begin (photophobia, nausea). cAMP-mediated smooth muscle relaxation at maximal effect.
After infusion cessation, plasma CGRP levels decline rapidly (t1/2 ~6.9 minutes). Hemodynamic parameters begin normalizing within 10-15 minutes post-infusion. Flushing resolves. However, endosomal CLR/RAMP1 signaling may sustain intracellular cAMP elevation beyond peptide clearance.
Plasma CGRP fully cleared. In migraine-susceptible subjects, delayed migraine-like headache develops in 60-75% of individuals, typically peaking 1-5 hours post-infusion. This delayed headache likely reflects sustained trigeminal sensitization and central processing rather than ongoing peripheral CGRP signaling.
Complete resolution of direct hemodynamic effects. Migraine-like headache, if triggered, may persist for hours and responds to standard migraine treatments including triptans. Cardioprotective effects observed in preclinical ischemia models peak during the early reperfusion period following CGRP pre-treatment.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 0.5mcg | Single dose |
| Moderate | 1.5mcg | Single dose |
| Aggressive | 3mcg | Single dose |
Note: CGRP (Calcitonin Gene-Related Peptide) is a 37-amino-acid neuropeptide existing as two isoforms: alpha-CGRP (encoded by the CALCA gene via alternative splicing of calcitonin mRNA) and beta-CGRP (encoded by the separate CALCB gene). Alpha-CGRP predominates in the central and peripheral nervous system, while beta-CGRP is found primarily in the enteric nervous system. CGRP is the most potent endogenous vasodilator known, approximately 1,000 times more potent than acetylcholine and 10 times more potent than prostaglandins on a molar basis. It is widely distributed in sensory C-fibers and A-delta fibers of trigeminal and dorsal root ganglia. CGRP became the central therapeutic target in migraine after the landmark discovery that serum CGRP levels are elevated during migraine attacks and that intravenous CGRP infusion triggers migraine-like headache in susceptible individuals. This led to the development of anti-CGRP monoclonal antibodies (erenumab targeting the CGRP receptor; fremanezumab, galcanezumab, and eptinezumab targeting the CGRP ligand) and small-molecule CGRP receptor antagonists (gepants: ubrogepant, rimegepant, atogepant), all FDA-approved for migraine prevention or acute treatment. The CGRP peptide itself remains a research-only compound with no approved therapeutic indication. Exogenous CGRP administration has been investigated in preclinical and early clinical studies for wound healing, cardioprotection, and vascular conditions, but development has been limited by its extremely short half-life, potent hypotensive effects, and flushing. Dosing values shown are derived from intravenous infusion studies in human volunteers and should not be interpreted as therapeutic dosing guidance. CGRP carries significant cardiovascular risks at higher doses and should only be handled in controlled research environments with hemodynamic monitoring.
How to Inject CGRP (Calcitonin Gene-Related Peptide)
FOR RESEARCH USE ONLY. CGRP peptide is reconstituted by adding bacteriostatic water to the lyophilized vial — gently swirl until dissolved, do not vortex. CGRP is highly susceptible to adsorption to glass and plastic surfaces; use siliconized or low-binding containers and add carrier protein (0.1% BSA) to diluent for accurate dosing at low concentrations. In human research studies, CGRP has been administered by intravenous infusion at rates of 0.5-3 mcg/min for 20 minutes, with continuous blood pressure and heart rate monitoring. Subcutaneous injection has been used in limited studies. The peptide has an extremely short plasma half-life (~6.9 minutes), requiring continuous infusion for sustained pharmacological effect. IV access, continuous telemetry monitoring, and vasopressor availability are mandatory for any human administration. Subjects should be supine during infusion. CGRP provokes migraine-like headache in migraine-susceptible individuals and should not be administered to active migraineurs. Dose titration should start at the lowest effective level with real-time hemodynamic assessment.
Cycling Protocol
No established human cycling protocol exists for exogenous CGRP administration. The extremely short half-life (~6.9 minutes) necessitates continuous IV infusion for sustained effects, which is impractical outside controlled research settings. Human infusion studies have typically used single-dose protocols (1.5-3 mcg/min for 20 minutes). Repeated dosing may lead to tachyphylaxis of vasodilatory responses. Cycling parameters shown are theoretical placeholders. Any investigational use requires continuous hemodynamic monitoring.
Pharmacokinetics
Source: Plasma t1/2 of alpha-CGRP is approximately 6.9 minutes in humans following IV infusion. Rapid clearance via neutral endopeptidase (NEP) degradation and hepatic/renal elimination (Kraenzlin et al., 1985, PMID 3489420; Brain & Grant, 2004, PMID 15207852)
Loading the interactive decay curve.
Side Effects
The most prominent side effect of exogenous CGRP administration is profound vasodilation leading to facial flushing, warmth, and cutaneous erythema, occurring in the majority of subjects at pharmacological doses. Dose-dependent hypotension is a significant concern, with systolic blood pressure reductions of 10-30 mmHg reported in IV infusion studies. Reflex tachycardia occurs secondary to vasodilation. CGRP infusion reliably triggers migraine-like headache in approximately 60-75% of migraine-susceptible individuals, typically within 1-5 hours, and can provoke headache even in healthy volunteers at higher doses. Nausea and a sensation of warmth or heat throughout the body are commonly reported. Dizziness and lightheadedness related to blood pressure reduction may occur. Local injection site reactions (erythema, warmth) reflect local vasodilatory effects. Palpitations have been noted in some infusion studies. At high doses, significant hypotension may require volume support or vasopressor intervention. Long-term effects of exogenous CGRP administration are unknown, as studies have been limited to single infusions or short courses. Theoretical concerns include exacerbation of inflammatory conditions (CGRP promotes neurogenic inflammation) and interference with bone metabolism. CAUTION: CGRP administration should only be performed in controlled research settings with continuous hemodynamic monitoring, IV access, and vasopressor availability due to risk of clinically significant hypotension.
Contraindications
- Hypotension or hemodynamic instability — CGRP causes potent vasodilation
- Active migraine or history of frequent migraine attacks — CGRP infusion triggers migraine-like headache
- Severe cardiovascular disease including decompensated heart failure
- Concurrent use of potent antihypertensive agents — risk of additive hypotension
- Pregnancy and breastfeeding — insufficient safety data; potential effects on placental blood flow
- Known hypersensitivity to CGRP or calcitonin family peptides
- Severe hepatic impairment affecting peptide clearance
- Raynaud phenomenon or vasospastic conditions (paradoxical rebound risk)
- Settings without continuous hemodynamic monitoring and vasopressor access
- Pediatric populations (no safety data for exogenous administration)
Drug Interactions
- Antihypertensive agents (all classes) — additive hypotension with CGRP-mediated vasodilation
- Nitrates and phosphodiesterase-5 inhibitors (sildenafil, tadalafil) — synergistic vasodilation and severe hypotension risk
- Triptans (sumatriptan, rizatriptan) — functional antagonism; triptans inhibit CGRP release from trigeminal neurons
- Anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) — direct pharmacological antagonism
- CGRP receptor antagonists (gepants: ubrogepant, rimegepant, atogepant) — block CGRP receptor activation
- Calcium channel blockers — additive vasodilation and hemodynamic effects
- Beta-blockers — may blunt compensatory tachycardia, worsening hypotensive episodes
- ACE inhibitors and ARBs — additive blood pressure reduction
- Capsaicin (high-dose) — depletes CGRP from sensory nerve terminals; may reduce endogenous CGRP reserve
- Botulinum toxin (onabotulinumtoxinA) — inhibits CGRP release from trigeminal neurons; used therapeutically in chronic migraine
Storage & Stability
Molecular Profile
Related Peptides
References
- Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular systemPubMed 2473557
- CGRP and its receptors provide new insights into migraine pathophysiologyReview
- CGRP as the target of new migraine therapies — successful translation from bench to clinicReview
- Calcitonin gene-related peptide (CGRP): a new target for migraineReview
- CGRP and migraine: neurogenic inflammation revisitedPubMed 22343045
- Calcitonin gene-related peptide is a potent vasodilator in humansPubMed 3489420